1. Leukotriene antagonists: As firstline asthmatic therapy: A review
- Author
-
Wozniak, Greta, Kotrotsiou, E., Roupa, Z., and Wozniak, Greta [0000-0002-8939-0927]
- Subjects
Leukotriene e4 ,Leukotriene antagonists ,Review ,Leukotriene receptor blocking agent ,Leukotriene a4 ,Leukotriene c4 ,Pranlukast ,Exercise induced asthma ,immune system diseases ,Zileuton ,Acetylsalicylic acid ,Allergen ,Chronic inflammation ,Leukotriene b4 ,Asthma ,respiratory tract diseases ,Leukotriene d4 ,Treatment ,Arachidonate 5 lipoxygenase activating protein ,Airway obstruction ,Zafirlukast ,Slow reacting substance ,Forced expiratory volume ,Human ,Leukotriene ,Montelukast - Abstract
Asthma is a chronic inflammatory disorder characterized by airflow obstruction. The development of leukotriene receptor antagonists and synthesis inhibitors in briefly described; and acute exercise, allergen, and aspirin challenge, studies with these agents are reviewed. Clinical studies with leukotriene antagonists and inhibitors have confirmed the central role leukotrienes of in asthma. The new generation of leukotriene receptor antagonist may be suitable as first-line therapy in patients with mild to moderate asthma. 23 3 305 312
- Published
- 2005